Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology

The diagnostic potential of PET using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imagin...

Full description

Saved in:
Bibliographic Details
Published inNuclear medicine and biology Vol. 92; pp. 78 - 84
Main Authors Stegmayr, Carina, Stoffels, Gabriele, Filß, Christian, Heinzel, Alexander, Lohmann, Philipp, Willuweit, Antje, Ermert, Johannes, Coenen, Heinz H., Mottaghy, Felix M., Galldiks, Norbert, Langen, Karl-Josef
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2021
Elsevier BV
Subjects
Amino acids
Brain
Brain cancer
Brain metastasis
Brain tumor diagnosis
Brain tumors
Cerebral glioma
Diagnostic systems
Fluorine isotopes
Labeling
Magnetic resonance imaging
Methionine
Neuroimaging
O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
PET
Pharmacokinetics
Positron emission
Positron emission tomography
Radiolabelled amino acids
Tomography
Tracers
Tumors
Tyrosine
Brain tumor diagnosis
O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
Brain metastasis
Radiolabelled amino acids
PET
Cerebral glioma
O-(2-[F]fluoroethyl)-L-tyrosine (FET)
Online AccessGet full text

Cover

Abstract The diagnostic potential of PET using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [18F]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [18F]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [18F]FET has widely replaced short lived amino acid tracers such as L-[11C]methyl-methionine ([11C]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [18F]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [18F]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed.
AbstractList The diagnostic potential of PET using the amino acid analogue O-(2-[ F]fluoroethyl)-L-tyrosine ([ F]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [ F]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [ F]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [ F]FET has widely replaced short lived amino acid tracers such as L-[ C]methyl-methionine ([ C]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [ F]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [ F]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed.
The diagnostic potential of PET using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [18F]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [18F]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [18F]FET has widely replaced short lived amino acid tracers such as L-[11C]methyl-methionine ([11C]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [18F]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [18F]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed.
The diagnostic potential of PET using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [18F]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [18F]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [18F]FET has widely replaced short lived amino acid tracers such as L-[11C]methyl-methionine ([11C]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [18F]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [18F]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed.The diagnostic potential of PET using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [18F]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [18F]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [18F]FET has widely replaced short lived amino acid tracers such as L-[11C]methyl-methionine ([11C]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [18F]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [18F]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed.
Author Willuweit, Antje
Coenen, Heinz H.
Mottaghy, Felix M.
Lohmann, Philipp
Filß, Christian
Stegmayr, Carina
Ermert, Johannes
Langen, Karl-Josef
Galldiks, Norbert
Heinzel, Alexander
Stoffels, Gabriele
Author_xml – sequence: 1
  givenname: Carina
  surname: Stegmayr
  fullname: Stegmayr, Carina
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 2
  givenname: Gabriele
  surname: Stoffels
  fullname: Stoffels, Gabriele
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 3
  givenname: Christian
  surname: Filß
  fullname: Filß, Christian
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 4
  givenname: Alexander
  surname: Heinzel
  fullname: Heinzel, Alexander
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 5
  givenname: Philipp
  surname: Lohmann
  fullname: Lohmann, Philipp
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 6
  givenname: Antje
  surname: Willuweit
  fullname: Willuweit, Antje
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 7
  givenname: Johannes
  surname: Ermert
  fullname: Ermert, Johannes
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 8
  givenname: Heinz H.
  surname: Coenen
  fullname: Coenen, Heinz H.
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 9
  givenname: Felix M.
  surname: Mottaghy
  fullname: Mottaghy, Felix M.
  organization: Dept. of Nuclear Medicine, RWTH University Hospital, Aachen, Germany
– sequence: 10
  givenname: Norbert
  surname: Galldiks
  fullname: Galldiks, Norbert
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
– sequence: 11
  givenname: Karl-Josef
  surname: Langen
  fullname: Langen, Karl-Josef
  email: k.j.langen@fz-juelich.de
  organization: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5), Forschungszentrum Juelich, Juelich, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32113820$$D View this record in MEDLINE/PubMed
BookMark eNqNkc9v0zAYhi00xLrBvwCRuHSHBPuL48QHhKaKAVKlXeACQlbifGUuqb35B1L-e1w6duipF_vg53llve8FObPOIiFvGK0YZeLdtrJJ73AcjKuAAq0oVJSKZ2TBuhZKKRg_IwsqhSw72rBzchHClmaTM_qCnNfAWN0BXZDvq-Q92ljEfI6hMLaId1ikgIXbFLflEsofrLv5uZmS8w7j3Txdlesyzt4FY7FY_nu9-fj1aq9aTN45q93kfs0vyfNNPwV89Xhfkm-ZW30u17efvqyu16VugMVSj7wD0EOta6wl1KPQYpS0ZUK3vEPGa82lFCARcaAMx4ZixwVQ3eEwNH19SZaH3HvvHhKGqHYmaJym3qJLQUEtZNcK3kBG3x6hW5e8zb9TwGULwEVLM_X6kUpD7ljde7Pr_az-t5aB9gDo3ELwuHlCGFX7fdRWPe2j9vsoCirvk833R6Y2sY_G2eh7M53gXx98zIX-MehV0AatxtF41FGNzpyQ8eEoQ0_GGt1Pv3E-KeEvee_D_w
CitedBy_id crossref_primary_10_3390_cancers14143336
crossref_primary_10_1002_ange_202313838
crossref_primary_10_1038_s41568_023_00576_4
crossref_primary_10_3390_cancers15010098
crossref_primary_10_3390_pharmaceutics14102196
crossref_primary_10_36290_neu_2023_026
crossref_primary_10_1021_acs_jpcb_1c08343
crossref_primary_10_1016_j_ymeth_2021_02_011
crossref_primary_10_3390_diagnostics12051202
crossref_primary_10_1007_s11060_022_04089_2
crossref_primary_10_1002_anie_202313838
crossref_primary_10_1007_s00259_023_06505_9
crossref_primary_10_1016_j_nucmedbio_2022_01_002
crossref_primary_10_1186_s12943_024_02113_9
crossref_primary_10_1556_650_2023_32812
crossref_primary_10_3390_ijms22083867
crossref_primary_10_3389_fnume_2022_850414
crossref_primary_10_3390_molecules28176192
crossref_primary_10_1002_ajoc_202300412
crossref_primary_10_1007_s40336_022_00523_7
crossref_primary_10_1016_j_jocn_2021_11_023
crossref_primary_10_1016_j_cpet_2024_09_003
crossref_primary_10_3390_tomography8040170
crossref_primary_10_3389_fonc_2022_939260
crossref_primary_10_1088_2057_1976_acba9e
crossref_primary_10_1007_s11912_021_01020_2
Cites_doi 10.1007/s00259-018-4188-8
10.1093/neuonc/not199
10.1016/j.radonc.2019.12.005
10.2967/jnumed.116.176610
10.2967/jnumed.115.171033
10.1016/j.nucmedbio.2009.05.005
10.2967/jnumed.111.098590
10.2967/jnumed.106.037895
10.1007/s00259-012-2093-0
10.1227/01.NEU.0000171642.49553.B0
10.2967/jnumed.113.123836
10.2967/jnumed.110.086645
10.1016/j.radonc.2011.03.006
10.1002/ijc.29259
10.1007/s00259-018-4082-4
10.1007/s11060-014-1594-z
10.1093/brain/awh399
10.1016/j.apradiso.2019.07.006
10.1007/s00259-004-1590-1
10.1093/neuonc/nov118
10.1093/noajnl/vdz038
10.1007/s00259-002-0780-y
10.2967/jnumed.113.122333
10.1016/S1470-2045(18)30675-2
10.1371/journal.pone.0141153
10.2174/1874471012666190111111046
10.1093/neuonc/now154
10.1016/j.nucmedbio.2011.01.006
10.1093/neuonc/noq196
10.2967/jnumed.112.103069
10.1007/s00259-019-04477-3
10.1097/WCO.0b013e328332363e
10.1186/s13014-016-0713-8
10.1016/j.wneu.2018.09.139
10.1007/s00259-010-1457-6
10.2967/jnumed.112.109603
10.1007/s00259-018-3969-4
10.1097/RLU.0000000000001152
10.1007/s00259-012-2251-4
10.23736/S1824-4785.18.03095-9
10.1093/neuonc/nos300
10.1016/j.ejrad.2018.04.003
10.1007/s00259-017-3846-6
10.1007/s00259-015-3140-4
10.1007/s00259-007-0534-y
10.1158/1078-0432.CCR-15-1334
10.1016/j.nicl.2018.08.024
10.1007/s00259-005-0053-7
10.1016/j.nucmedbio.2006.12.007
10.2967/jnumed.112.103325
10.1007/s00259-018-4207-9
10.1007/s00066-011-0060-5
10.3389/fonc.2019.00814
10.1007/s00259-003-1118-0
10.1093/neuonc/noz083
10.2967/jnumed.114.144675
10.1016/S0969-8043(02)00225-7
10.1016/j.nucmedbio.2006.01.002
10.1007/s00259-012-2109-9
10.1007/s00726-014-1863-3
10.1093/neuonc/noz003
10.1088/0031-9155/54/18/012
10.1007/s12094-017-1816-x
10.1007/s00401-007-0243-4
10.1016/j.wneu.2016.02.032
10.1007/s00259-006-0206-3
10.1007/s00259-004-1705-8
10.1007/s00401-016-1545-1
10.1016/S1470-2045(08)70125-6
10.1080/14737175.2020.1704256
10.1093/neuonc/nox153
10.1007/s00330-015-3691-6
10.2967/jnumed.116.180612
10.1200/JCO.2007.12.2440
10.1016/j.wneu.2016.01.085
10.1007/s00259-019-04656-2
10.1007/s00259-019-04384-7
10.1038/nrneurol.2017.44
10.1212/WNL.0000000000001262
10.2967/jnumed.109.071423
10.2967/jnumed.111.096859
10.1007/s10967-016-4900-8
10.1016/j.ymeth.2017.05.019
10.2967/jnumed.119.225680
10.1097/RLU.0b013e3182291b40
10.3389/fneur.2016.00120
10.1186/s12885-016-2806-z
10.1007/s00330-016-4638-2
10.1016/j.nucmedbio.2006.09.004
10.1212/WNL.0b013e31821d74e7
10.1093/jn/136.1.218S
10.1007/s00259-014-2959-4
10.2967/jnumed.107.046615
10.1016/j.nucmedbio.2011.01.001
10.1093/neuonc/nos259
10.1097/RLU.0000000000002890
10.1007/s00259-015-3274-4
10.1007/s00259-015-3276-2
10.2147/OTT.S87126
10.1016/j.ijrobp.2010.01.055
10.1371/journal.pone.0140917
10.1093/neuonc/now058
10.1007/s11307-019-01357-y
10.1053/j.semnuclmed.2012.06.001
10.1016/j.nucmedbio.2019.05.006
10.1016/j.bmc.2009.09.029
10.2967/jnumed.113.120089
10.1016/S0969-8051(03)00023-4
10.2310/7290.2013.00056
10.1007/s00259-005-1819-7
ContentType Journal Article
Copyright 2020 Elsevier Inc.
Copyright © 2020 Elsevier Inc. All rights reserved.
Copyright Elsevier BV Jan 2021
Copyright_xml – notice: 2020 Elsevier Inc.
– notice: Copyright © 2020 Elsevier Inc. All rights reserved.
– notice: Copyright Elsevier BV Jan 2021
DBID AAYXX
CITATION
NPM
7QO
7QP
7TK
7TM
8FD
FR3
P64
7X8
DOI 10.1016/j.nucmedbio.2020.02.006
DatabaseName CrossRef
PubMed
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed
Biotechnology Research Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Physics
EISSN 1872-9614
EndPage 84
ExternalDocumentID 32113820
10_1016_j_nucmedbio_2020_02_006
S0969805120300299
Genre Journal Article
Review
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29N
4.4
457
4CK
4G.
53G
5RE
5VS
7-5
71M
8P~
8WZ
9JM
A6W
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABGSF
ABJNI
ABLJU
ABMAC
ABMZM
ABUDA
ABWVN
ABXDB
ABZDS
ACDAQ
ACGFS
ACIEU
ACIUM
ACIWK
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEI
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OI~
OU0
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RNS
ROL
RPZ
SAE
SDF
SDG
SEL
SES
SEW
SPCBC
SSH
SSP
SSU
SSZ
T5K
UHS
WH7
WUQ
Z5R
~G-
AACTN
AAIAV
AATCM
ABLVK
ABYKQ
AFKWA
AJBFU
AJOXV
AMFUW
DOVZS
EFLBG
LCYCR
RIG
ZA5
AAYXX
AFCTW
AGRNS
CITATION
NPM
7QO
7QP
7TK
7TM
8FD
FR3
P64
7X8
ID FETCH-LOGICAL-c521t-cd4822cb3c3e3923d6c6d90716c748e143c499629eeeb01ed50e84620c8ebb5a3
IEDL.DBID .~1
ISSN 0969-8051
1872-9614
IngestDate Mon Jul 21 09:53:11 EDT 2025
Wed Aug 13 04:41:15 EDT 2025
Mon Jul 21 06:03:04 EDT 2025
Tue Jul 01 03:54:16 EDT 2025
Thu Apr 24 23:03:34 EDT 2025
Fri Feb 23 02:45:15 EST 2024
Tue Aug 26 17:14:35 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Brain tumor diagnosis
O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
Brain metastasis
Radiolabelled amino acids
PET
Cerebral glioma
O-(2-[F]fluoroethyl)-L-tyrosine (FET)
Language English
License Copyright © 2020 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c521t-cd4822cb3c3e3923d6c6d90716c748e143c499629eeeb01ed50e84620c8ebb5a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMID 32113820
PQID 2497224670
PQPubID 2045423
PageCount 7
ParticipantIDs proquest_miscellaneous_2369876452
proquest_journals_2497224670
pubmed_primary_32113820
crossref_primary_10_1016_j_nucmedbio_2020_02_006
crossref_citationtrail_10_1016_j_nucmedbio_2020_02_006
elsevier_sciencedirect_doi_10_1016_j_nucmedbio_2020_02_006
elsevier_clinicalkey_doi_10_1016_j_nucmedbio_2020_02_006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2021
2021-01-00
2021-Jan
20210101
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: January 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Oxford
PublicationTitle Nuclear medicine and biology
PublicationTitleAlternate Nucl Med Biol
PublicationYear 2021
Publisher Elsevier Inc
Elsevier BV
Publisher_xml – name: Elsevier Inc
– name: Elsevier BV
References Unterrainer, Winkelmann, Suchorska, Giese, Wenter, Kreth (bb0335) 2018; 45
Kaim, Weber, Kurrer, Westera, Schweitzer, Gottschalk (bb0620) 2002; 29
Ceccon, Lohmann, Stoffels, Judov, Filss, Rapp (bb0255) 2017; 19
Pauleit, Floeth, Hamacher, Riemenschneider, Reifenberger, Muller (bb0190) 2005; 128
Heiss, Mayer, Herz, Wester, Schwaiger, Senekowitsch-Schmidtke (bb0115) 1999; 40
Pyka, Hiob, Preibisch, Gempt, Wiestler, Schlegel (bb0515) 2018; 103
Orlovskaya, Fedorova, Nadporojskii, Krasikova (bb0095) 2019; 152
Jansen, Graute, Armbruster, Suchorska, Lutz, Eigenbrod (bb0285) 2012; 39
Piroth, Holy, Pinkawa, Stoffels, Kaiser, Galldiks (bb0375) 2011; 99
Bogni, Laera, Cucchi, Iwata, Seregni, Pascali (bb0085) 2019; 72–73
Bette, Gempt, Delbridge, Kirschke, Schlegel, Foerster (bb0385) 2016; 89
Oehlke, Mix, Graf, Schimek-Jasch, Nestle, Gotz (bb0425) 2016; 16
Lopez, Cordeiro, Albicker, Doostkam, Nikkhah, Kirch (bb0430) 2015; 8
Galldiks, Langen (bb0015) 2016; 7
Fleischmann, Unterrainer, Schon, Corradini, Maihofer, Bartenstein (bb0420) 2020; 145
Heinzel, Stock, Langen, Muller (bb0640) 2012; 39
Pauleit, Stoffels, Bachofner, Floeth, Sabel, Herzog (bb0410) 2009; 36
Herholz, Langen, Schiepers, Mountz (bb0035) 2012; 42
Jansen, Suchorska, Wenter, Eigenbrod, Schmid-Tannwald, Zwergal (bb0195) 2014; 55
Verger, Stoffels, Bauer, Lohmann, Blau, Fink (bb0325) 2018; 45
Hamacher, Coenen (bb0075) 2002; 57
Pöpperl, Götz, Rachinger, Schnell, Gildehaus, Tonn (bb0595) 2006; 33
Kebir, Rauschenbach, Galldiks, Schlaak, Hattingen, Landsberg (bb0480) 2016; 18
Mueller, Klette, Kalb, Baum (bb0070) 2011; 38
Romagna, Unterrainer, Schmid-Tannwald, Brendel, Tonn, Nachbichler (bb0535) 2016; 11
Pöpperl, Kreth, Mehrkens, Herms, Seelos, Koch (bb0235) 2007; 34
Jena, Taneja, Gambhir, Mishra, D’Souza, Verma (bb0520) 2016; 41
Galldiks, Werner, Tscherpel, Fink, Langen (bb0575) 2019; 1
Pöpperl, Goldbrunner, Gildehaus, Kreth, Tanner, Holtmannspotter (bb0590) 2005; 32
Unterrainer, Schweisthal, Suchorska, Wenter, Schmid-Tannwald, Fendler (bb0395) 2016; 57
Rapp, Heinzel, Galldiks, Stoffels, Felsberg, Ewelt (bb0295) 2013; 54
Piroth, Pinkawa, Holy, Klotz, Schaar, Stoffels (bb0415) 2012; 188
Lahoutte, Caveliers, Camargo, Franca, Ramadan, Veljkovic (bb0130) 2004; 45
Swissmedic (bb0045) 2014; 13
Richard, Fouquet, Lebel, Lepage (bb0165) 2017; 58
Galldiks, Stoffels, Filss, Rapp, Blau, Tscherpel (bb0495) 2015; 17
Pöpperl, Kreth, Mehrkens, Herms, Seelos, Koch (bb0290) 2007; 34
Bolcaen, Lybaert, Moerman, Descamps, Deblaere, Boterberg (bb0170) 2016; 11
Klasner, Buchmann, Gempt, Ringel, Lapa, Krause (bb0445) 2015; 10
Pauleit, Floeth, Herzog, Hamacher, Tellmann, Muller (bb0105) 2003; 30
Pyka, Gempt, Hiob, Ringel, Schlegel, Bette (bb0370) 2016; 43
Stegmayr, Willuweit, Lohmann, Langen (bb0205) 2019; 12
Galldiks, Langen, Pope (bb0215) 2015; 17
Jansen, Suchorska, Wenter, Eigenbrod, Schmid-Tannwald, Zwergal (bb0310) 2014; 55
Akhoundova, Hiltbrunner, Mader, Forster, Kraft, Schwanhausser (bb0540) 2020; 45
Wester, Herz, Weber, Heiss, Senekowitsch-Schmidtke, Schwaiger (bb0060) 1999; 40
Galldiks, Stoffels, Ruge, Rapp, Sabel, Reifenberger (bb0305) 2013; 54
Delgado-Lopez, Rinones-Mena, Corrales-Garcia (bb0490) 2018; 20
Heiss, Wienhard, Wagner, Lanfermann, Thiel, Herholz (bb0040) 1996; 37
Galldiks, Rapp, Stoffels, Fink, Shah, Coenen (bb0555) 2013; 40
Zuhayra, Alfteimi, Forstner, Lützen, Meller, Henze (bb0065) 2009; 17
Kratochwil, Combs, Leotta, Afshar-Oromieh, Rieken, Debus (bb0160) 2014; 16
Prante, Blaser, Maschauer, Kuwert (bb0140) 2007; 34
Maurer, Brucker, Stoffels, Filipski, Filss, Mottaghy (bb0510) 2019
Lakshminarayanan, Kumar, Roy, Pawar, Chaudhari, Rajan (bb0090) 2016; 310
Langen, Hamacher, Weckesser, Floeth, Stoffels, Bauer (bb0120) 2006; 33
Albert, Winkelmann, Suchorska, Wenter, Schmid-Tannwald, Mille (bb0210) 2016; 43
Galldiks, Unterrainer, Judov, Stoffels, Rapp, Lohmann (bb0350) 2019; 21
Vredenburgh, Desjardins, Herndon, Marcello, Reardon, Quinn (bb0550) 2007; 25
Floeth, Pauleit, Sabel, Reifenberger, Stoffels, Stummer (bb0625) 2006; 47
Shoup, Olson, Hoffman, Votaw, Eshima, Eshima (bb0055) 1999; 40
Galldiks, Dunkl, Ceccon, Tscherpel, Stoffels, Law (bb0565) 2018; 45
Galldiks, Langen, Holy, Pinkawa, Stoffels, Nolte (bb0580) 2012; 53
Langen, Jarosch, Muhlensiepen, Hamacher, Broer, Jansen (bb0110) 2003; 30
Weckesser, Langen, Rickert, Kloska, Straeter, Hamacher (bb0225) 2005; 32
Habermeier, Graf, Sandhofer, Boissel, Roesch, Closs (bb0135) 2015; 47
Hutterer, Ebner, Riemenschneider, Willuweit, McCoy, Egger (bb0635) 2017; 58
Langen, Bartenstein, Boecker, Brust, Coenen, Drzezga (bb0185) 2011; 50
Galldiks, Langen (bb0010) 2015; 59
Lombardi, De Salvo, Brandes, Eoli, Ruda, Faedi (bb0570) 2019; 20
Lohmann, Kocher, Ceccon, Bauer, Stoffels, Viswanathan (bb0360) 2018; 20
Thiele, Ehmer, Piroth, Eble, Coenen, Kaiser (bb0155) 2009; 54
Buchmann, Klasner, Gempt, Bauer, Pyka, Delbridge (bb0440) 2016; 89
Salber, Stoffels, Pauleit, Oros-Peusquens, Shah, Klauth (bb0615) 2007; 48
Bourdier, Greguric, Roselt, Jackson, Faragalla, Katsifis (bb0080) 2011; 38
Langen, Galldiks, Hattingen, Shah (bb0020) 2017; 13
Galldiks, Dunkl, Stoffels, Hutterer, Rapp, Sabel (bb0475) 2015; 42
Werner, Stoffels, Lichtenstein, Borggrefe, Lohmann, Ceccon (bb0525) 2019; 46
Calcagni, Galli, Giordano, Taralli, Anile, Niesen (bb0230) 2011; 36
Suchorska, Jansen, Linn, Kretzschmar, Janssen, Eigenbrod (bb0380) 2015; 84
Kebir, Fimmers, Galldiks, Schafer, Mack, Schaub (bb0485) 2016; 22
Malkowski, Harat, Zyromska, Wisniewski, Harat, Lopatto (bb0265) 2015; 10
Lohmann, Stoffels, Ceccon, Rapp, Sabel, Filss (bb0545) 2017; 27
Langen, Stoffels, Filss, Heinzel, Stegmayr, Lohmann (bb0175) 2017; 130
Langen, Galldiks, Hattingen, Shah (bb0005) 2017; 13
Hutterer, Nowosielski, Putzer, Jansen, Seiz, Schocke (bb0275) 2013; 15
Hutterer, Nowosielski, Putzer, Waitz, Tinkhauser, Kostron (bb0560) 2011; 52
Salber, Stoffels, Oros-Peusquens, Shah, Reifenberger, Hamacher (bb0605) 2010; 51
Baguet, Verhoeven, De Vos, Goethals (bb0650) 2019; 9
Young, Gupta, Shah, Graber, Zhang, Shi (bb0465) 2011; 76
Brandsma, van den Bent (bb0470) 2009; 22
Piroth, Liebenstund, Galldiks, Stoffels, Shah, Eble (bb0260) 2013; 12
Dunet, Rossier, Buck, Stupp, Prior (bb0270) 2012; 53
Louis, Perry, Reifenberger, von Deimling, Figarella-Branger, Cavenee (bb0320) 2016; 131
Buchmann, Gempt, Ryang, Pyka, Kirschke, Meyer (bb0450) 2019; 121
Thon, Kunz, Lemke, Jansen, Eigenbrod, Kreth (bb0245) 2015; 136
Vander Borght, Asenbaum, Bartenstein, Halldin, Kapucu, Van Laere (bb0180) 2006; 33
Rapp, Heinzel, Galldiks, Stoffels, Felsberg, Ewelt (bb0280) 2013; 54
Law, Albert, Arbizu, Boellaard, Drzezga, Galldiks (bb0100) 2019; 46
Lohmann, Kocher, Steger, Galldiks (bb0365) 2018; 62
Verburg, Koopman, Yaqub, Hoekstra, Lammertsma, Barkhof (bb0435) 2019
Langen, Tonn, Weller, Galldiks (bb0050) 2014; 120
Stegmayr, Schoneck, Oliveira, Willuweit, Filss, Galldiks (bb0200) 2016; 43
Kertels, Kessler, Mihovilovic, Stolzenburg, Linsenmann, Samnick (bb0345) 2019; 21
Song, Cheng, Ma, Wang, Dong, Wei (bb0400) 2020
Lohmann, Stavrinou, Lipke, Bauer, Ceccon, Werner (bb0405) 2019; 46
Pichler, Dunzinger, Wurm, Pichler, Weis, Nussbaumer (bb0630) 2010; 37
Geisler, Stegmayr, Niemitz, Lohmann, Rapp, Stoffels (bb0455) 2019; 60
Suchorska, Giese, Biczok, Unterrainer, Weller, Drexler (bb0355) 2018; 20
Galldiks, Langen, Albert, Chamberlain, Soffietti, Kim (bb0030) 2019; 21
Pauleit, Stoffels, Schaden, Hamacher, Bauer, Tellmann (bb0150) 2005; 46
Piroth, Pinkawa, Holy, Klotz, Nussen, Stoffels (bb0585) 2011; 80
Vettermann, Suchorska, Unterrainer, Nelwan, Forbrig, Ruf (bb0330) 2019; 46
Floeth, Pauleit, Sabel, Stoffels, Reifenberger, Riemenschneider (bb0340) 2007; 48
Galldiks, Stoffels, Ruge, Rapp, Sabel, Reifenberger (bb0390) 2013; 54
Heinzel, Muller, Langen, Blaum, Verburg, Mottaghy (bb0645) 2013; 54
Rachinger, Goetz, Popperl, Gildehaus, Kreth, Holtmannspotter (bb0505) 2005; 57
Salber, Stoffels, Pauleit, Reifenberger, Sabel, Shah (bb0610) 2006; 33
Albert, Weller, Suchorska, Galldiks, Soffietti, Kim (bb0025) 2016; 18
Lohmann, Herzog, Rota Kops, Stoffels, Judov, Filss (bb0315) 2015; 25
Hawkins, O’Kane, Simpson, Vina (bb0125) 2006; 136
Jansen, Suchorska, Wenter, Schmid-Tannwald, Todica, Eigenbrod (bb0250) 2015; 56
Langen, Heinzel, Lohmann, Mottaghy, Galldiks (bb0600) 2020; 20
Galldiks, Stoffels, Filss, Piroth, Sabel, Ruge (bb0530) 2012; 53
Pöpperl, Gotz, Rachinger, Gildehaus, Tonn, Tatsch (bb0500) 2004; 31
Wiriyasermkul, Nagamori, Tominaga, Oriuchi, Kaira, Nakao (bb0145) 2012; 53
Brandsma, Stalpers, Taal, Sminia, van den Bent (bb0460) 2008; 9
Kunz, Thon, Eigenbrod, Hartmann, Egensperger, Herms (bb0240) 2011; 13
Jansen, Schwartz, Graute, Eigenbrod, Lutz, Egensperger (bb0300) 2012; 14
Louis, Ohgaki, Wiestler, Cavenee, Burger, Jouvet (bb0220) 2007; 114
Pyka (10.1016/j.nucmedbio.2020.02.006_bb0370) 2016; 43
Langen (10.1016/j.nucmedbio.2020.02.006_bb0600) 2020; 20
Song (10.1016/j.nucmedbio.2020.02.006_bb0400) 2020
Kaim (10.1016/j.nucmedbio.2020.02.006_bb0620) 2002; 29
Pauleit (10.1016/j.nucmedbio.2020.02.006_bb0190) 2005; 128
Hutterer (10.1016/j.nucmedbio.2020.02.006_bb0635) 2017; 58
Lohmann (10.1016/j.nucmedbio.2020.02.006_bb0365) 2018; 62
Kebir (10.1016/j.nucmedbio.2020.02.006_bb0485) 2016; 22
Albert (10.1016/j.nucmedbio.2020.02.006_bb0210) 2016; 43
Heiss (10.1016/j.nucmedbio.2020.02.006_bb0115) 1999; 40
Jansen (10.1016/j.nucmedbio.2020.02.006_bb0310) 2014; 55
Hamacher (10.1016/j.nucmedbio.2020.02.006_bb0075) 2002; 57
Lahoutte (10.1016/j.nucmedbio.2020.02.006_bb0130) 2004; 45
Louis (10.1016/j.nucmedbio.2020.02.006_bb0220) 2007; 114
Calcagni (10.1016/j.nucmedbio.2020.02.006_bb0230) 2011; 36
Buchmann (10.1016/j.nucmedbio.2020.02.006_bb0440) 2016; 89
Lakshminarayanan (10.1016/j.nucmedbio.2020.02.006_bb0090) 2016; 310
Suchorska (10.1016/j.nucmedbio.2020.02.006_bb0355) 2018; 20
Habermeier (10.1016/j.nucmedbio.2020.02.006_bb0135) 2015; 47
Stegmayr (10.1016/j.nucmedbio.2020.02.006_bb0205) 2019; 12
Brandsma (10.1016/j.nucmedbio.2020.02.006_bb0470) 2009; 22
Pauleit (10.1016/j.nucmedbio.2020.02.006_bb0105) 2003; 30
Brandsma (10.1016/j.nucmedbio.2020.02.006_bb0460) 2008; 9
Stegmayr (10.1016/j.nucmedbio.2020.02.006_bb0200) 2016; 43
Orlovskaya (10.1016/j.nucmedbio.2020.02.006_bb0095) 2019; 152
Vredenburgh (10.1016/j.nucmedbio.2020.02.006_bb0550) 2007; 25
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0390) 2013; 54
Prante (10.1016/j.nucmedbio.2020.02.006_bb0140) 2007; 34
Hutterer (10.1016/j.nucmedbio.2020.02.006_bb0560) 2011; 52
Wester (10.1016/j.nucmedbio.2020.02.006_bb0060) 1999; 40
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0215) 2015; 17
Bourdier (10.1016/j.nucmedbio.2020.02.006_bb0080) 2011; 38
Wiriyasermkul (10.1016/j.nucmedbio.2020.02.006_bb0145) 2012; 53
Pauleit (10.1016/j.nucmedbio.2020.02.006_bb0410) 2009; 36
Lohmann (10.1016/j.nucmedbio.2020.02.006_bb0360) 2018; 20
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0580) 2012; 53
Salber (10.1016/j.nucmedbio.2020.02.006_bb0610) 2006; 33
Pyka (10.1016/j.nucmedbio.2020.02.006_bb0515) 2018; 103
Lohmann (10.1016/j.nucmedbio.2020.02.006_bb0545) 2017; 27
Baguet (10.1016/j.nucmedbio.2020.02.006_bb0650) 2019; 9
Rapp (10.1016/j.nucmedbio.2020.02.006_bb0280) 2013; 54
Lohmann (10.1016/j.nucmedbio.2020.02.006_bb0405) 2019; 46
Swissmedic (10.1016/j.nucmedbio.2020.02.006_bb0045) 2014; 13
Heinzel (10.1016/j.nucmedbio.2020.02.006_bb0640) 2012; 39
Heinzel (10.1016/j.nucmedbio.2020.02.006_bb0645) 2013; 54
Pöpperl (10.1016/j.nucmedbio.2020.02.006_bb0235) 2007; 34
Jansen (10.1016/j.nucmedbio.2020.02.006_bb0285) 2012; 39
Floeth (10.1016/j.nucmedbio.2020.02.006_bb0340) 2007; 48
Jansen (10.1016/j.nucmedbio.2020.02.006_bb0300) 2012; 14
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0475) 2015; 42
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0015) 2016; 7
Langen (10.1016/j.nucmedbio.2020.02.006_bb0185) 2011; 50
Pöpperl (10.1016/j.nucmedbio.2020.02.006_bb0500) 2004; 31
Maurer (10.1016/j.nucmedbio.2020.02.006_bb0510) 2019
Young (10.1016/j.nucmedbio.2020.02.006_bb0465) 2011; 76
Geisler (10.1016/j.nucmedbio.2020.02.006_bb0455) 2019; 60
Zuhayra (10.1016/j.nucmedbio.2020.02.006_bb0065) 2009; 17
Dunet (10.1016/j.nucmedbio.2020.02.006_bb0270) 2012; 53
Pauleit (10.1016/j.nucmedbio.2020.02.006_bb0150) 2005; 46
Pöpperl (10.1016/j.nucmedbio.2020.02.006_bb0595) 2006; 33
Vander Borght (10.1016/j.nucmedbio.2020.02.006_bb0180) 2006; 33
Unterrainer (10.1016/j.nucmedbio.2020.02.006_bb0395) 2016; 57
Thon (10.1016/j.nucmedbio.2020.02.006_bb0245) 2015; 136
Bette (10.1016/j.nucmedbio.2020.02.006_bb0385) 2016; 89
Bolcaen (10.1016/j.nucmedbio.2020.02.006_bb0170) 2016; 11
Langen (10.1016/j.nucmedbio.2020.02.006_bb0020) 2017; 13
Pöpperl (10.1016/j.nucmedbio.2020.02.006_bb0590) 2005; 32
Louis (10.1016/j.nucmedbio.2020.02.006_bb0320) 2016; 131
Langen (10.1016/j.nucmedbio.2020.02.006_bb0175) 2017; 130
Rachinger (10.1016/j.nucmedbio.2020.02.006_bb0505) 2005; 57
Langen (10.1016/j.nucmedbio.2020.02.006_bb0050) 2014; 120
Kunz (10.1016/j.nucmedbio.2020.02.006_bb0240) 2011; 13
Hutterer (10.1016/j.nucmedbio.2020.02.006_bb0275) 2013; 15
Floeth (10.1016/j.nucmedbio.2020.02.006_bb0625) 2006; 47
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0010) 2015; 59
Shoup (10.1016/j.nucmedbio.2020.02.006_bb0055) 1999; 40
Kertels (10.1016/j.nucmedbio.2020.02.006_bb0345) 2019; 21
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0530) 2012; 53
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0555) 2013; 40
Akhoundova (10.1016/j.nucmedbio.2020.02.006_bb0540) 2020; 45
Lombardi (10.1016/j.nucmedbio.2020.02.006_bb0570) 2019; 20
Salber (10.1016/j.nucmedbio.2020.02.006_bb0615) 2007; 48
Pöpperl (10.1016/j.nucmedbio.2020.02.006_bb0290) 2007; 34
Piroth (10.1016/j.nucmedbio.2020.02.006_bb0375) 2011; 99
Langen (10.1016/j.nucmedbio.2020.02.006_bb0110) 2003; 30
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0495) 2015; 17
Pichler (10.1016/j.nucmedbio.2020.02.006_bb0630) 2010; 37
Albert (10.1016/j.nucmedbio.2020.02.006_bb0025) 2016; 18
Bogni (10.1016/j.nucmedbio.2020.02.006_bb0085) 2019; 72–73
Langen (10.1016/j.nucmedbio.2020.02.006_bb0005) 2017; 13
Heiss (10.1016/j.nucmedbio.2020.02.006_bb0040) 1996; 37
Klasner (10.1016/j.nucmedbio.2020.02.006_bb0445) 2015; 10
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0575) 2019; 1
Kebir (10.1016/j.nucmedbio.2020.02.006_bb0480) 2016; 18
Romagna (10.1016/j.nucmedbio.2020.02.006_bb0535) 2016; 11
Vettermann (10.1016/j.nucmedbio.2020.02.006_bb0330) 2019; 46
Malkowski (10.1016/j.nucmedbio.2020.02.006_bb0265) 2015; 10
Herholz (10.1016/j.nucmedbio.2020.02.006_bb0035) 2012; 42
Suchorska (10.1016/j.nucmedbio.2020.02.006_bb0380) 2015; 84
Lopez (10.1016/j.nucmedbio.2020.02.006_bb0430) 2015; 8
Buchmann (10.1016/j.nucmedbio.2020.02.006_bb0450) 2019; 121
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0030) 2019; 21
Kratochwil (10.1016/j.nucmedbio.2020.02.006_bb0160) 2014; 16
Weckesser (10.1016/j.nucmedbio.2020.02.006_bb0225) 2005; 32
Hawkins (10.1016/j.nucmedbio.2020.02.006_bb0125) 2006; 136
Jansen (10.1016/j.nucmedbio.2020.02.006_bb0195) 2014; 55
Delgado-Lopez (10.1016/j.nucmedbio.2020.02.006_bb0490) 2018; 20
Verger (10.1016/j.nucmedbio.2020.02.006_bb0325) 2018; 45
Piroth (10.1016/j.nucmedbio.2020.02.006_bb0415) 2012; 188
Salber (10.1016/j.nucmedbio.2020.02.006_bb0605) 2010; 51
Unterrainer (10.1016/j.nucmedbio.2020.02.006_bb0335) 2018; 45
Mueller (10.1016/j.nucmedbio.2020.02.006_bb0070) 2011; 38
Thiele (10.1016/j.nucmedbio.2020.02.006_bb0155) 2009; 54
Richard (10.1016/j.nucmedbio.2020.02.006_bb0165) 2017; 58
Piroth (10.1016/j.nucmedbio.2020.02.006_bb0585) 2011; 80
Ceccon (10.1016/j.nucmedbio.2020.02.006_bb0255) 2017; 19
Langen (10.1016/j.nucmedbio.2020.02.006_bb0120) 2006; 33
Jansen (10.1016/j.nucmedbio.2020.02.006_bb0250) 2015; 56
Rapp (10.1016/j.nucmedbio.2020.02.006_bb0295) 2013; 54
Oehlke (10.1016/j.nucmedbio.2020.02.006_bb0425) 2016; 16
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0305) 2013; 54
Law (10.1016/j.nucmedbio.2020.02.006_bb0100) 2019; 46
Verburg (10.1016/j.nucmedbio.2020.02.006_bb0435) 2019
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0565) 2018; 45
Werner (10.1016/j.nucmedbio.2020.02.006_bb0525) 2019; 46
Lohmann (10.1016/j.nucmedbio.2020.02.006_bb0315) 2015; 25
Piroth (10.1016/j.nucmedbio.2020.02.006_bb0260) 2013; 12
Jena (10.1016/j.nucmedbio.2020.02.006_bb0520) 2016; 41
Fleischmann (10.1016/j.nucmedbio.2020.02.006_bb0420) 2020; 145
Galldiks (10.1016/j.nucmedbio.2020.02.006_bb0350) 2019; 21
References_xml – volume: 58
  start-page: 1278
  year: 2017
  end-page: 1284
  ident: bb0165
  article-title: Determination of an optimal pharmacokinetic model of (18)F-FET for quantitative applications in rat brain tumors
  publication-title: J Nucl Med
– volume: 45
  start-page: 1242
  year: 2018
  end-page: 1249
  ident: bb0335
  article-title: Biological tumour volumes of gliomas in early and standard 20-40 min (18)F-FET PET images differ according to IDH mutation status
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 36
  start-page: 779
  year: 2009
  end-page: 787
  ident: bb0410
  article-title: Comparison of F-18-FET and F-18-FDG PET in brain tumors
  publication-title: Nucl Med Biol
– volume: 16
  start-page: 434
  year: 2014
  end-page: 440
  ident: bb0160
  article-title: Intra-individual comparison of (18)F-FET and (18)F-DOPA in PET imaging of recurrent brain tumors
  publication-title: Neuro-oncology
– volume: 9
  start-page: 453
  year: 2008
  end-page: 461
  ident: bb0460
  article-title: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
  publication-title: Lancet Oncol
– volume: 34
  start-page: 305
  year: 2007
  end-page: 314
  ident: bb0140
  article-title: In vitro characterization of the thyroidal uptake of O-(2-[(18)F]fluoroethyl)-L-tyrosine
  publication-title: Nucl Med Biol
– volume: 310
  start-page: 991
  year: 2016
  end-page: 999
  ident: bb0090
  article-title: Fully automated synthesis of O-(2′-[
  publication-title: J Radioanal Nucl Chem
– volume: 46
  start-page: 2581
  year: 2019
  end-page: 2589
  ident: bb0330
  article-title: Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic (18)F-FET PET
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 136
  start-page: 2132
  year: 2015
  end-page: 2145
  ident: bb0245
  article-title: Dynamic F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses
  publication-title: Int J Cancer
– volume: 48
  start-page: 519
  year: 2007
  end-page: 527
  ident: bb0340
  article-title: Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma
  publication-title: Journal of nuclear medicine : official publication
– volume: 11
  year: 2016
  ident: bb0170
  article-title: Kinetic modeling and graphical analysis of 18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET) and 18F-fluorodeoxyglucose (FDG) PET for the fiscrimination between high-grade glioma and radiation necrosis in rats
  publication-title: PloS one
– volume: 39
  start-page: 1089
  year: 2012
  end-page: 1096
  ident: bb0640
  article-title: Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 13
  start-page: 279
  year: 2017
  end-page: 289
  ident: bb0005
  article-title: Advances in neuro-oncology imaging
  publication-title: Nat Rev Neurol
– volume: 57
  start-page: 853
  year: 2002
  end-page: 856
  ident: bb0075
  article-title: Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine
  publication-title: Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine
– volume: 48
  start-page: 2056
  year: 2007
  end-page: 2062
  ident: bb0615
  article-title: Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses
  publication-title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
– volume: 58
  start-page: 129
  year: 2017
  end-page: 137
  ident: bb0635
  article-title: Epileptic activity increases cerebral amino acid transport assessed by 18F-fluoroethyl-l-tyrosine amino acid PET: a potential brain tumor mimic
  publication-title: Society of Nuclear Medicine
– volume: 33
  start-page: 1374
  year: 2006
  end-page: 1380
  ident: bb0180
  article-title: EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 46
  start-page: 591
  year: 2019
  end-page: 602
  ident: bb0405
  article-title: FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma
  publication-title: Eur J Nucl Med Mol Imaging
– year: 2019
  ident: bb0510
  article-title: (18)F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience
  publication-title: J Nucl Med
– volume: 19
  start-page: 281
  year: 2017
  end-page: 288
  ident: bb0255
  article-title: Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy
  publication-title: Neuro Oncol
– volume: 21
  start-page: 1174
  year: 2019
  end-page: 1181
  ident: bb0345
  article-title: Prognostic value of O-(2-[(18)F]fluoroethyl)-L-tyrosine PET/CT in newly diagnosed WHO 2016 grade II and III glioma
  publication-title: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
– volume: 62
  start-page: 272
  year: 2018
  end-page: 280
  ident: bb0365
  article-title: Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas
  publication-title: Q J Nucl Med Mol Imaging
– volume: 18
  start-page: 1462
  year: 2016
  end-page: 1464
  ident: bb0480
  article-title: Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases
  publication-title: Neuro-oncology
– volume: 56
  start-page: 9
  year: 2015
  end-page: 15
  ident: bb0250
  article-title: Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma
  publication-title: Journal of nuclear medicine : official publication
– volume: 10
  year: 2015
  ident: bb0265
  article-title: The sum of tumour-to-brain ratios improves the accuracy of diagnosing gliomas using 18F-FET PET
  publication-title: PloS one
– volume: 27
  start-page: 2916
  year: 2017
  end-page: 2927
  ident: bb0545
  article-title: Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans
  publication-title: Eur Radiol
– volume: 13
  start-page: 651
  year: 2014
  ident: bb0045
  article-title: Swiss agency for therapeutic products
  publication-title: Journal Swissmedic
– volume: 45
  start-page: 1591
  year: 2004
  end-page: 1596
  ident: bb0130
  article-title: SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation
  publication-title: Society of Nuclear Medicine
– volume: 53
  start-page: 1367
  year: 2012
  end-page: 1374
  ident: bb0530
  article-title: Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis
  publication-title: Society of Nuclear Medicine
– volume: 22
  start-page: 633
  year: 2009
  end-page: 638
  ident: bb0470
  article-title: Pseudoprogression and pseudoresponse in the treatment of gliomas
  publication-title: Curr Opin Neurol
– volume: 47
  start-page: 776
  year: 2006
  end-page: 782
  ident: bb0625
  article-title: 18F-FET PET differentiation of ring-enhancing brain lesions
  publication-title: Society of Nuclear Medicine
– volume: 99
  start-page: 218
  year: 2011
  end-page: 224
  ident: bb0375
  article-title: Prognostic impact of postoperative, pre-irradiation F-18-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy
  publication-title: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
– volume: 18
  start-page: 1199
  year: 2016
  end-page: 1208
  ident: bb0025
  article-title: Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
  publication-title: Neuro-oncology
– volume: 30
  start-page: 501
  year: 2003
  end-page: 508
  ident: bb0110
  article-title: Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas
  publication-title: Nucl Med Biol
– volume: 121
  year: 2019
  ident: bb0450
  article-title: Can early postoperative O-(2-(18F)fluoroethyl)-l-tyrosine positron emission tomography after resection of glioblastoma predict the location of later tumor recurrence?
  publication-title: World Neurosurg
– volume: 32
  start-page: 422
  year: 2005
  end-page: 429
  ident: bb0225
  article-title: O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 11
  start-page: 139
  year: 2016
  ident: bb0535
  article-title: Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?
  publication-title: Radiat Oncol
– volume: 42
  start-page: 685
  year: 2015
  end-page: 695
  ident: bb0475
  article-title: Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 89
  start-page: 420
  year: 2016
  end-page: 426
  ident: bb0440
  article-title: (18)F-fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: a comparison with standard postoperative magnetic resonance imaging
  publication-title: World Neurosurg
– volume: 80
  start-page: 176
  year: 2011
  end-page: 184
  ident: bb0585
  article-title: Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 10
  year: 2015
  ident: bb0445
  article-title: Early [18F]FET-PET in gliomas after surgical resection: comparison with MRI and histopathology
  publication-title: PloS one
– volume: 120
  start-page: 665
  year: 2014
  end-page: 666
  ident: bb0050
  article-title: Letter to the editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435-460]
  publication-title: J Neurooncol
– year: 2020
  ident: bb0400
  article-title: Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 20
  start-page: 279
  year: 2018
  end-page: 288
  ident: bb0355
  article-title: Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
  publication-title: Neuro-oncology
– volume: 15
  start-page: 341
  year: 2013
  end-page: 351
  ident: bb0275
  article-title: [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma
  publication-title: Neuro-oncology
– volume: 54
  start-page: 229
  year: 2013
  end-page: 235
  ident: bb0295
  article-title: Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma
  publication-title: J Nucl Med
– volume: 41
  start-page: e228
  year: 2016
  end-page: e236
  ident: bb0520
  article-title: Glioma recurrence versus radiation necrosis: single-session multiparametric approach using simultaneous O-(2-18F-fluoroethyl)-L-tyrosine PET/MRI
  publication-title: Clin Nucl Med
– volume: 13
  start-page: 307
  year: 2011
  end-page: 316
  ident: bb0240
  article-title: Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
  publication-title: Neuro-oncology
– volume: 45
  start-page: 443
  year: 2018
  end-page: 451
  ident: bb0325
  article-title: Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 43
  start-page: 133
  year: 2016
  end-page: 141
  ident: bb0370
  article-title: Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 55
  start-page: 198
  year: 2014
  end-page: 203
  ident: bb0310
  article-title: Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients
  publication-title: J Nucl Med
– volume: 52
  start-page: 856
  year: 2011
  end-page: 864
  ident: bb0560
  article-title: O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma
  publication-title: J Nucl Med
– volume: 47
  start-page: 335
  year: 2015
  end-page: 344
  ident: bb0135
  article-title: System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET)
  publication-title: Amino Acids
– volume: 12
  start-page: 201
  year: 2019
  end-page: 210
  ident: bb0205
  article-title: O-(2-[18F]-Fluoroethyl)-L-tyrosine (FET) in neurooncology: a review of experimental results
  publication-title: Curr Radiopharm
– volume: 40
  start-page: 331
  year: 1999
  end-page: 338
  ident: bb0055
  article-title: Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors
  publication-title: Society of Nuclear Medicine
– volume: 40
  start-page: 205
  year: 1999
  end-page: 212
  ident: bb0060
  article-title: Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging
  publication-title: Society of Nuclear Medicine
– volume: 12
  start-page: 388
  year: 2013
  end-page: 395
  ident: bb0260
  article-title: Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-(1)(8)Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
  publication-title: Mol Imaging
– volume: 57
  start-page: 505
  year: 2005
  end-page: 511
  ident: bb0505
  article-title: Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas
  publication-title: Neurosurgery
– volume: 59
  start-page: 70
  year: 2015
  end-page: 82
  ident: bb0010
  article-title: Applications of PET imaging of neurological tumors with radiolabeled amino acids
  publication-title: Q J Nucl Med Mol Imaging
– volume: 33
  start-page: 792
  year: 2006
  end-page: 800
  ident: bb0595
  article-title: Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 89
  start-page: 230
  year: 2016
  end-page: 239
  ident: bb0385
  article-title: Prognostic value of O-(2-[18F]-Fluoroethyl)-L-tyrosine-positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma
  publication-title: World Neurosurg
– volume: 8
  start-page: 3803
  year: 2015
  end-page: 3815
  ident: bb0430
  article-title: Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool
  publication-title: OncoTargets and therapy
– volume: 51
  start-page: 790
  year: 2010
  end-page: 797
  ident: bb0605
  article-title: Comparison of O-(2-18F-fluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas
  publication-title: Journal of nuclear medicine : official publication
– volume: 40
  start-page: 1367
  year: 1999
  end-page: 1373
  ident: bb0115
  article-title: Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo
  publication-title: Society of Nuclear Medicine
– volume: 103
  start-page: 32
  year: 2018
  end-page: 37
  ident: bb0515
  article-title: Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI
  publication-title: Eur J Radiol
– volume: 145
  start-page: 49
  year: 2020
  end-page: 55
  ident: bb0420
  article-title: Margin reduction in radiotherapy for glioblastoma through (18)F-fluoroethyltyrosine PET? - a recurrence pattern analysis
  publication-title: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
– volume: 53
  start-page: 1048
  year: 2012
  end-page: 1057
  ident: bb0580
  article-title: Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI
  publication-title: Society of Nuclear Medicine
– volume: 22
  start-page: 2190
  year: 2016
  end-page: 2196
  ident: bb0485
  article-title: Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET
  publication-title: Clinical cancer research : an official journal of the American Association for Cancer Research
– volume: 20
  start-page: 137
  year: 2020
  end-page: 146
  ident: bb0600
  article-title: Advantages and limitations of amino acid PET for tracking therapy response in glioma patients
  publication-title: Expert Rev Neurother
– volume: 72–73
  start-page: 11
  year: 2019
  end-page: 19
  ident: bb0085
  article-title: An improved automated one-pot synthesis of O-(2-[
  publication-title: Nucl Med Biol
– volume: 46
  start-page: 540
  year: 2019
  end-page: 557
  ident: bb0100
  article-title: Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 55
  start-page: 198
  year: 2014
  end-page: 203
  ident: bb0195
  article-title: Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients
  publication-title: Journal of nuclear medicine : official publication
– volume: 14
  start-page: 1473
  year: 2012
  end-page: 1480
  ident: bb0300
  article-title: Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas
  publication-title: Neuro-oncology
– volume: 54
  start-page: 2046
  year: 2013
  end-page: 2054
  ident: bb0305
  article-title: Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma
  publication-title: J Nucl Med
– volume: 21
  start-page: 585
  year: 2019
  end-page: 595
  ident: bb0030
  article-title: PET imaging in patients with brain metastasis-report of the RANO/PET group
  publication-title: Neuro-oncology
– volume: 53
  start-page: 1253
  year: 2012
  end-page: 1261
  ident: bb0145
  article-title: Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET
  publication-title: J Nucl Med
– volume: 46
  start-page: 411
  year: 2005
  end-page: 416
  ident: bb0150
  article-title: PET with O-(2-18F-Fluoroethyl)-L-tyrosine in peripheral tumors: first clinical results
  publication-title: J Nucl Med
– volume: 9
  start-page: 814
  year: 2019
  ident: bb0650
  article-title: Cost-effectiveness of [(18)F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma
  publication-title: Front Oncol
– volume: 30
  start-page: 519
  year: 2003
  end-page: 524
  ident: bb0105
  article-title: Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 60
  start-page: 1373
  year: 2019
  end-page: 1379
  ident: bb0455
  article-title: Treatment-related uptake of O-(2-(18)F-fluoroethyl)-l-tyrosine and l-[methyl-(3)H]-methionine after tumor resection in rat glioma models
  publication-title: Society of Nuclear Medicine
– volume: 76
  start-page: 1918
  year: 2011
  end-page: 1924
  ident: bb0465
  article-title: Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
  publication-title: Neurology
– volume: 31
  start-page: 1464
  year: 2004
  end-page: 1470
  ident: bb0500
  article-title: Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 50
  start-page: 167
  year: 2011
  end-page: 173
  ident: bb0185
  article-title: German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids
  publication-title: Nuklearmedizin Nuclear medicine
– volume: 34
  start-page: 1933
  year: 2007
  end-page: 1942
  ident: bb0235
  article-title: FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 54
  start-page: 229
  year: 2013
  end-page: 235
  ident: bb0280
  article-title: Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma
  publication-title: Society of Nuclear Medicine
– volume: 17
  start-page: 1434
  year: 2015
  end-page: 1444
  ident: bb0215
  article-title: From the clinician’s point of view - what is the status quo of positron emission tomography in patients with brain tumors?
  publication-title: Neuro-oncology
– volume: 32
  start-page: 1018
  year: 2005
  end-page: 1025
  ident: bb0590
  article-title: O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 17
  start-page: 7441
  year: 2009
  end-page: 7448
  ident: bb0065
  article-title: New approach for the synthesis of [
  publication-title: Bioorg Med Chem
– volume: 21
  start-page: 1331
  year: 2019
  end-page: 1338
  ident: bb0350
  article-title: Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients
  publication-title: Neuro-oncology
– volume: 29
  start-page: 648
  year: 2002
  end-page: 654
  ident: bb0620
  article-title: (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 136
  year: 2006
  ident: bb0125
  article-title: Structure of the blood-brain barrier and its role in the transport of amino acids
  publication-title: Journal of Nutrition
– volume: 37
  start-page: 1521
  year: 2010
  end-page: 1528
  ident: bb0630
  article-title: Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 53
  start-page: 207
  year: 2012
  end-page: 214
  ident: bb0270
  article-title: Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis
  publication-title: Journal of nuclear medicine: official publication, Society of Nuclear Medicine
– volume: 34
  start-page: 1933
  year: 2007
  end-page: 1942
  ident: bb0290
  article-title: FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 45
  start-page: 2377
  year: 2018
  end-page: 2386
  ident: bb0565
  article-title: Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 37
  start-page: 1180
  year: 1996
  end-page: 1182
  ident: bb0040
  article-title: F-Dopa as an amino acid tracer to detect brain tumors
  publication-title: Society of Nuclear Medicine
– volume: 43
  start-page: 1105
  year: 2016
  end-page: 1114
  ident: bb0210
  article-title: Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 38
  start-page: 653
  year: 2011
  end-page: 658
  ident: bb0070
  article-title: Synthesis of O-(2-[
  publication-title: Nucl Med Biol
– year: 2019
  ident: bb0435
  article-title: Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study
  publication-title: Neuro Oncol
– volume: 17
  start-page: 1293
  year: 2015
  end-page: 1300
  ident: bb0495
  article-title: The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
  publication-title: Neuro-oncology
– volume: 54
  start-page: 1217
  year: 2013
  end-page: 1222
  ident: bb0645
  article-title: The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis
  publication-title: Journal of nuclear medicine : official publication
– volume: 7
  start-page: 120
  year: 2016
  ident: bb0015
  article-title: Amino acid PET - an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence?
  publication-title: Front Neurol
– volume: 54
  start-page: 2046
  year: 2013
  end-page: 2054
  ident: bb0390
  article-title: Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma
  publication-title: Journal of nuclear medicine : official publication
– volume: 54
  start-page: 5525
  year: 2009
  end-page: 5539
  ident: bb0155
  article-title: The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma
  publication-title: Phys Med Biol
– volume: 25
  start-page: 3017
  year: 2015
  end-page: 3024
  ident: bb0315
  article-title: Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas
  publication-title: Eur Radiol
– volume: 84
  start-page: 710
  year: 2015
  end-page: 719
  ident: bb0380
  article-title: Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM
  publication-title: Neurology
– volume: 43
  start-page: 1115
  year: 2016
  end-page: 1123
  ident: bb0200
  article-title: Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 20
  start-page: 110
  year: 2019
  end-page: 119
  ident: bb0570
  article-title: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
  publication-title: Lancet Oncol
– volume: 20
  start-page: 939
  year: 2018
  end-page: 953
  ident: bb0490
  article-title: Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis
  publication-title: Clin Transl Oncol
– volume: 39
  start-page: 1021
  year: 2012
  end-page: 1029
  ident: bb0285
  article-title: MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 33
  start-page: 1029
  year: 2006
  end-page: 1035
  ident: bb0610
  article-title: Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia
  publication-title: Nucl Med Biol
– volume: 25
  start-page: 4722
  year: 2007
  end-page: 4729
  ident: bb0550
  article-title: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
  publication-title: J Clin Oncol
– volume: 57
  start-page: 1177
  year: 2016
  end-page: 1182
  ident: bb0395
  article-title: Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma - does it make sense? Journal of nuclear medicine: official publication
  publication-title: J Nucl Med
– volume: 33
  start-page: 287
  year: 2006
  end-page: 294
  ident: bb0120
  article-title: O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications
  publication-title: Nucl Med Biol
– volume: 42
  start-page: 356
  year: 2012
  end-page: 370
  ident: bb0035
  article-title: Brain tumors
  publication-title: Semin Nucl Med
– volume: 46
  start-page: 1889
  year: 2019
  end-page: 1901
  ident: bb0525
  article-title: Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 16
  start-page: 769
  year: 2016
  ident: bb0425
  article-title: Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1)
  publication-title: BMC Cancer
– volume: 114
  start-page: 97
  year: 2007
  end-page: 109
  ident: bb0220
  article-title: The 2007 WHO classification of tumours of the central nervous system
  publication-title: Acta Neuropathol
– volume: 36
  start-page: 841
  year: 2011
  end-page: 847
  ident: bb0230
  article-title: Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy
  publication-title: Clin Nucl Med
– volume: 20
  start-page: 537
  year: 2018
  end-page: 542
  ident: bb0360
  article-title: Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis
  publication-title: NeuroImage Clinical
– volume: 45
  start-page: 113
  year: 2020
  end-page: 117
  ident: bb0540
  article-title: 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer
  publication-title: Clin Nucl Med
– volume: 131
  start-page: 803
  year: 2016
  end-page: 820
  ident: bb0320
  article-title: The 2016 World Health Organization classification of tumors of the central nervous system: a summary
  publication-title: Acta Neuropathol
– volume: 130
  start-page: 124
  year: 2017
  end-page: 134
  ident: bb0175
  article-title: Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)
  publication-title: Methods
– volume: 38
  start-page: 645
  year: 2011
  end-page: 651
  ident: bb0080
  article-title: Fully automated one-pot radiosynthesis of O-(2-[
  publication-title: Nucl Med Biol
– volume: 188
  start-page: 334
  year: 2012
  end-page: 339
  ident: bb0415
  article-title: Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study
  publication-title: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]
– volume: 40
  start-page: 22
  year: 2013
  end-page: 33
  ident: bb0555
  article-title: Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 128
  start-page: 678
  year: 2005
  end-page: 687
  ident: bb0190
  article-title: O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas
  publication-title: Brain : a journal of neurology
– volume: 1
  year: 2019
  ident: bb0575
  article-title: Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
  publication-title: Neuro-Oncology Advances
– volume: 152
  start-page: 135
  year: 2019
  end-page: 139
  ident: bb0095
  article-title: A fully automated azeotropic drying free synthesis of O-(2-[
  publication-title: Appl Rad Isot
– volume: 13
  start-page: 279
  year: 2017
  end-page: 289
  ident: bb0020
  article-title: Advances in neuro-oncology imaging
  publication-title: Nat Rev Neurol
– volume: 46
  start-page: 591
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0405
  article-title: FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-018-4188-8
– volume: 16
  start-page: 434
  year: 2014
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0160
  article-title: Intra-individual comparison of (18)F-FET and (18)F-DOPA in PET imaging of recurrent brain tumors
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/not199
– volume: 145
  start-page: 49
  year: 2020
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0420
  article-title: Margin reduction in radiotherapy for glioblastoma through (18)F-fluoroethyltyrosine PET? - a recurrence pattern analysis
  publication-title: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  doi: 10.1016/j.radonc.2019.12.005
– year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0435
  article-title: Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study
  publication-title: Neuro Oncol
– volume: 58
  start-page: 129
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0635
  article-title: Epileptic activity increases cerebral amino acid transport assessed by 18F-fluoroethyl-l-tyrosine amino acid PET: a potential brain tumor mimic
  publication-title: Society of Nuclear Medicine
  doi: 10.2967/jnumed.116.176610
– volume: 19
  start-page: 281
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0255
  article-title: Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy
  publication-title: Neuro Oncol
– volume: 57
  start-page: 1177
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0395
  article-title: Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma - does it make sense? Journal of nuclear medicine: official publication
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.115.171033
– volume: 40
  start-page: 331
  year: 1999
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0055
  article-title: Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors
  publication-title: Society of Nuclear Medicine
– volume: 36
  start-page: 779
  year: 2009
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0410
  article-title: Comparison of F-18-FET and F-18-FDG PET in brain tumors
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2009.05.005
– volume: 53
  start-page: 1048
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0580
  article-title: Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI
  publication-title: Society of Nuclear Medicine
  doi: 10.2967/jnumed.111.098590
– volume: 48
  start-page: 519
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0340
  article-title: Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma
  publication-title: Journal of nuclear medicine : official publication
  doi: 10.2967/jnumed.106.037895
– volume: 39
  start-page: 1089
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0640
  article-title: Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-012-2093-0
– volume: 11
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0170
  article-title: Kinetic modeling and graphical analysis of 18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET) and 18F-fluorodeoxyglucose (FDG) PET for the fiscrimination between high-grade glioma and radiation necrosis in rats
  publication-title: PloS one
– volume: 57
  start-page: 505
  year: 2005
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0505
  article-title: Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas
  publication-title: Neurosurgery
  doi: 10.1227/01.NEU.0000171642.49553.B0
– volume: 59
  start-page: 70
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0010
  article-title: Applications of PET imaging of neurological tumors with radiolabeled amino acids
  publication-title: Q J Nucl Med Mol Imaging
– volume: 54
  start-page: 2046
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0390
  article-title: Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma
  publication-title: Journal of nuclear medicine : official publication
  doi: 10.2967/jnumed.113.123836
– volume: 52
  start-page: 856
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0560
  article-title: O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.110.086645
– volume: 99
  start-page: 218
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0375
  article-title: Prognostic impact of postoperative, pre-irradiation F-18-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy
  publication-title: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  doi: 10.1016/j.radonc.2011.03.006
– volume: 136
  start-page: 2132
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0245
  article-title: Dynamic F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29259
– volume: 45
  start-page: 2377
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0565
  article-title: Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-018-4082-4
– volume: 120
  start-page: 665
  year: 2014
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0050
  article-title: Letter to the editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435-460]
  publication-title: J Neurooncol
  doi: 10.1007/s11060-014-1594-z
– volume: 128
  start-page: 678
  year: 2005
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0190
  article-title: O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas
  publication-title: Brain : a journal of neurology
  doi: 10.1093/brain/awh399
– volume: 152
  start-page: 135
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0095
  article-title: A fully automated azeotropic drying free synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) using tetrabutylammonium tosylate
  publication-title: Appl Rad Isot
  doi: 10.1016/j.apradiso.2019.07.006
– volume: 31
  start-page: 1464
  year: 2004
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0500
  article-title: Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-004-1590-1
– volume: 17
  start-page: 1434
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0215
  article-title: From the clinician’s point of view - what is the status quo of positron emission tomography in patients with brain tumors?
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/nov118
– volume: 1
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0575
  article-title: Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
  publication-title: Neuro-Oncology Advances
  doi: 10.1093/noajnl/vdz038
– volume: 29
  start-page: 648
  year: 2002
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0620
  article-title: (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-002-0780-y
– volume: 55
  start-page: 198
  year: 2014
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0310
  article-title: Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.113.122333
– volume: 20
  start-page: 110
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0570
  article-title: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30675-2
– volume: 10
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0445
  article-title: Early [18F]FET-PET in gliomas after surgical resection: comparison with MRI and histopathology
  publication-title: PloS one
  doi: 10.1371/journal.pone.0141153
– volume: 12
  start-page: 201
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0205
  article-title: O-(2-[18F]-Fluoroethyl)-L-tyrosine (FET) in neurooncology: a review of experimental results
  publication-title: Curr Radiopharm
  doi: 10.2174/1874471012666190111111046
– volume: 18
  start-page: 1462
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0480
  article-title: Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/now154
– volume: 38
  start-page: 653
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0070
  article-title: Synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine based on a cartridge purification method
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2011.01.006
– volume: 13
  start-page: 307
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0240
  article-title: Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/noq196
– volume: 53
  start-page: 1253
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0145
  article-title: Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.103069
– volume: 46
  start-page: 2581
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0330
  article-title: Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic (18)F-FET PET
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-019-04477-3
– volume: 22
  start-page: 633
  year: 2009
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0470
  article-title: Pseudoprogression and pseudoresponse in the treatment of gliomas
  publication-title: Curr Opin Neurol
  doi: 10.1097/WCO.0b013e328332363e
– volume: 11
  start-page: 139
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0535
  article-title: Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?
  publication-title: Radiat Oncol
  doi: 10.1186/s13014-016-0713-8
– volume: 121
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0450
  article-title: Can early postoperative O-(2-(18F)fluoroethyl)-l-tyrosine positron emission tomography after resection of glioblastoma predict the location of later tumor recurrence?
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2018.09.139
– volume: 37
  start-page: 1521
  year: 2010
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0630
  article-title: Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1457-6
– volume: 54
  start-page: 229
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0295
  article-title: Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.109603
– volume: 45
  start-page: 1242
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0335
  article-title: Biological tumour volumes of gliomas in early and standard 20-40 min (18)F-FET PET images differ according to IDH mutation status
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-018-3969-4
– volume: 41
  start-page: e228
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0520
  article-title: Glioma recurrence versus radiation necrosis: single-session multiparametric approach using simultaneous O-(2-18F-fluoroethyl)-L-tyrosine PET/MRI
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0000000000001152
– volume: 40
  start-page: 22
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0555
  article-title: Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-012-2251-4
– year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0510
  article-title: (18)F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience
  publication-title: J Nucl Med
– volume: 62
  start-page: 272
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0365
  article-title: Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas
  publication-title: Q J Nucl Med Mol Imaging
  doi: 10.23736/S1824-4785.18.03095-9
– volume: 15
  start-page: 341
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0275
  article-title: [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/nos300
– volume: 103
  start-page: 32
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0515
  article-title: Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI
  publication-title: Eur J Radiol
  doi: 10.1016/j.ejrad.2018.04.003
– volume: 45
  start-page: 443
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0325
  article-title: Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3846-6
– volume: 43
  start-page: 133
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0370
  article-title: Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-015-3140-4
– volume: 37
  start-page: 1180
  year: 1996
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0040
  article-title: F-Dopa as an amino acid tracer to detect brain tumors
  publication-title: Society of Nuclear Medicine
– volume: 34
  start-page: 1933
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0235
  article-title: FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-007-0534-y
– volume: 22
  start-page: 2190
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0485
  article-title: Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET
  publication-title: Clinical cancer research : an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-15-1334
– volume: 20
  start-page: 537
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0360
  article-title: Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis
  publication-title: NeuroImage Clinical
  doi: 10.1016/j.nicl.2018.08.024
– volume: 33
  start-page: 792
  year: 2006
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0595
  article-title: Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-005-0053-7
– volume: 34
  start-page: 305
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0140
  article-title: In vitro characterization of the thyroidal uptake of O-(2-[(18)F]fluoroethyl)-L-tyrosine
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2006.12.007
– volume: 53
  start-page: 1367
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0530
  article-title: Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis
  publication-title: Society of Nuclear Medicine
  doi: 10.2967/jnumed.112.103325
– volume: 46
  start-page: 540
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0100
  article-title: Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-018-4207-9
– volume: 188
  start-page: 334
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0415
  article-title: Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study
  publication-title: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]
  doi: 10.1007/s00066-011-0060-5
– volume: 9
  start-page: 814
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0650
  article-title: Cost-effectiveness of [(18)F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00814
– volume: 30
  start-page: 519
  year: 2003
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0105
  article-title: Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-003-1118-0
– volume: 54
  start-page: 229
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0280
  article-title: Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma
  publication-title: Society of Nuclear Medicine
  doi: 10.2967/jnumed.112.109603
– volume: 13
  start-page: 651
  year: 2014
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0045
  article-title: Swiss agency for therapeutic products
  publication-title: Journal Swissmedic
– volume: 21
  start-page: 1331
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0350
  article-title: Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/noz083
– volume: 56
  start-page: 9
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0250
  article-title: Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma
  publication-title: Journal of nuclear medicine : official publication
  doi: 10.2967/jnumed.114.144675
– volume: 57
  start-page: 853
  year: 2002
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0075
  article-title: Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine
  publication-title: Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine
  doi: 10.1016/S0969-8043(02)00225-7
– volume: 33
  start-page: 287
  year: 2006
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0120
  article-title: O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2006.01.002
– volume: 39
  start-page: 1021
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0285
  article-title: MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-012-2109-9
– volume: 40
  start-page: 1367
  year: 1999
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0115
  article-title: Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo
  publication-title: Society of Nuclear Medicine
– volume: 47
  start-page: 335
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0135
  article-title: System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET)
  publication-title: Amino Acids
  doi: 10.1007/s00726-014-1863-3
– volume: 21
  start-page: 585
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0030
  article-title: PET imaging in patients with brain metastasis-report of the RANO/PET group
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/noz003
– volume: 54
  start-page: 5525
  year: 2009
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0155
  article-title: The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma
  publication-title: Phys Med Biol
  doi: 10.1088/0031-9155/54/18/012
– volume: 20
  start-page: 939
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0490
  article-title: Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-017-1816-x
– volume: 114
  start-page: 97
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0220
  article-title: The 2007 WHO classification of tumours of the central nervous system
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-007-0243-4
– volume: 89
  start-page: 420
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0440
  article-title: (18)F-fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: a comparison with standard postoperative magnetic resonance imaging
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2016.02.032
– volume: 55
  start-page: 198
  year: 2014
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0195
  article-title: Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients
  publication-title: Journal of nuclear medicine : official publication
  doi: 10.2967/jnumed.113.122333
– volume: 33
  start-page: 1374
  year: 2006
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0180
  article-title: EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-006-0206-3
– volume: 32
  start-page: 422
  year: 2005
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0225
  article-title: O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-004-1705-8
– volume: 131
  start-page: 803
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0320
  article-title: The 2016 World Health Organization classification of tumors of the central nervous system: a summary
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-016-1545-1
– volume: 9
  start-page: 453
  year: 2008
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0460
  article-title: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70125-6
– volume: 20
  start-page: 137
  year: 2020
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0600
  article-title: Advantages and limitations of amino acid PET for tracking therapy response in glioma patients
  publication-title: Expert Rev Neurother
  doi: 10.1080/14737175.2020.1704256
– volume: 20
  start-page: 279
  year: 2018
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0355
  article-title: Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/nox153
– volume: 25
  start-page: 3017
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0315
  article-title: Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas
  publication-title: Eur Radiol
  doi: 10.1007/s00330-015-3691-6
– volume: 54
  start-page: 2046
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0305
  article-title: Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.113.123836
– volume: 58
  start-page: 1278
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0165
  article-title: Determination of an optimal pharmacokinetic model of (18)F-FET for quantitative applications in rat brain tumors
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.180612
– volume: 25
  start-page: 4722
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0550
  article-title: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.12.2440
– volume: 89
  start-page: 230
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0385
  article-title: Prognostic value of O-(2-[18F]-Fluoroethyl)-L-tyrosine-positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2016.01.085
– year: 2020
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0400
  article-title: Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-019-04656-2
– volume: 46
  start-page: 1889
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0525
  article-title: Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-019-04384-7
– volume: 13
  start-page: 279
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0005
  article-title: Advances in neuro-oncology imaging
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2017.44
– volume: 45
  start-page: 1591
  year: 2004
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0130
  article-title: SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation
  publication-title: Society of Nuclear Medicine
– volume: 84
  start-page: 710
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0380
  article-title: Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000001262
– volume: 47
  start-page: 776
  year: 2006
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0625
  article-title: 18F-FET PET differentiation of ring-enhancing brain lesions
  publication-title: Society of Nuclear Medicine
– volume: 51
  start-page: 790
  year: 2010
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0605
  article-title: Comparison of O-(2-18F-fluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas
  publication-title: Journal of nuclear medicine : official publication
  doi: 10.2967/jnumed.109.071423
– volume: 53
  start-page: 207
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0270
  article-title: Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis
  publication-title: Journal of nuclear medicine: official publication, Society of Nuclear Medicine
  doi: 10.2967/jnumed.111.096859
– volume: 310
  start-page: 991
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0090
  article-title: Fully automated synthesis of O-(2′-[18F]fluoroethyl)-L-tyrosine ([18F]FET) using solid phase extraction (SPE) purification with neutral alumina
  publication-title: J Radioanal Nucl Chem
  doi: 10.1007/s10967-016-4900-8
– volume: 130
  start-page: 124
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0175
  article-title: Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)
  publication-title: Methods
  doi: 10.1016/j.ymeth.2017.05.019
– volume: 60
  start-page: 1373
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0455
  article-title: Treatment-related uptake of O-(2-(18)F-fluoroethyl)-l-tyrosine and l-[methyl-(3)H]-methionine after tumor resection in rat glioma models
  publication-title: Society of Nuclear Medicine
  doi: 10.2967/jnumed.119.225680
– volume: 36
  start-page: 841
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0230
  article-title: Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0b013e3182291b40
– volume: 7
  start-page: 120
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0015
  article-title: Amino acid PET - an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence?
  publication-title: Front Neurol
  doi: 10.3389/fneur.2016.00120
– volume: 40
  start-page: 205
  year: 1999
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0060
  article-title: Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging
  publication-title: Society of Nuclear Medicine
– volume: 16
  start-page: 769
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0425
  article-title: Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1)
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2806-z
– volume: 27
  start-page: 2916
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0545
  article-title: Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans
  publication-title: Eur Radiol
  doi: 10.1007/s00330-016-4638-2
– volume: 33
  start-page: 1029
  year: 2006
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0610
  article-title: Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2006.09.004
– volume: 76
  start-page: 1918
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0465
  article-title: Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31821d74e7
– volume: 136
  year: 2006
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0125
  article-title: Structure of the blood-brain barrier and its role in the transport of amino acids
  publication-title: Journal of Nutrition
  doi: 10.1093/jn/136.1.218S
– volume: 42
  start-page: 685
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0475
  article-title: Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-014-2959-4
– volume: 48
  start-page: 2056
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0615
  article-title: Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses
  publication-title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
  doi: 10.2967/jnumed.107.046615
– volume: 38
  start-page: 645
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0080
  article-title: Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FXFN module
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2011.01.001
– volume: 14
  start-page: 1473
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0300
  article-title: Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/nos259
– volume: 45
  start-page: 113
  year: 2020
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0540
  article-title: 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0000000000002890
– volume: 34
  start-page: 1933
  year: 2007
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0290
  article-title: FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-007-0534-y
– volume: 43
  start-page: 1115
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0200
  article-title: Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-015-3274-4
– volume: 43
  start-page: 1105
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0210
  article-title: Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-015-3276-2
– volume: 8
  start-page: 3803
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0430
  article-title: Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool
  publication-title: OncoTargets and therapy
  doi: 10.2147/OTT.S87126
– volume: 80
  start-page: 176
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0585
  article-title: Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2010.01.055
– volume: 10
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0265
  article-title: The sum of tumour-to-brain ratios improves the accuracy of diagnosing gliomas using 18F-FET PET
  publication-title: PloS one
  doi: 10.1371/journal.pone.0140917
– volume: 18
  start-page: 1199
  year: 2016
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0025
  article-title: Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/now058
– volume: 21
  start-page: 1174
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0345
  article-title: Prognostic value of O-(2-[(18)F]fluoroethyl)-L-tyrosine PET/CT in newly diagnosed WHO 2016 grade II and III glioma
  publication-title: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  doi: 10.1007/s11307-019-01357-y
– volume: 42
  start-page: 356
  year: 2012
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0035
  article-title: Brain tumors
  publication-title: Semin Nucl Med
  doi: 10.1053/j.semnuclmed.2012.06.001
– volume: 72–73
  start-page: 11
  year: 2019
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0085
  article-title: An improved automated one-pot synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) based on a purification by cartridges
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2019.05.006
– volume: 17
  start-page: 7441
  year: 2009
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0065
  article-title: New approach for the synthesis of [18F]fluoroethyltyrosine for cancer imaging: simple, fast, and high yielding automated synthesis
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2009.09.029
– volume: 54
  start-page: 1217
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0645
  article-title: The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis
  publication-title: Journal of nuclear medicine : official publication
  doi: 10.2967/jnumed.113.120089
– volume: 17
  start-page: 1293
  year: 2015
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0495
  article-title: The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
  publication-title: Neuro-oncology
– volume: 30
  start-page: 501
  year: 2003
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0110
  article-title: Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas
  publication-title: Nucl Med Biol
  doi: 10.1016/S0969-8051(03)00023-4
– volume: 12
  start-page: 388
  year: 2013
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0260
  article-title: Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-(1)(8)Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
  publication-title: Mol Imaging
  doi: 10.2310/7290.2013.00056
– volume: 13
  start-page: 279
  year: 2017
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0020
  article-title: Advances in neuro-oncology imaging
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2017.44
– volume: 46
  start-page: 411
  year: 2005
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0150
  article-title: PET with O-(2-18F-Fluoroethyl)-L-tyrosine in peripheral tumors: first clinical results
  publication-title: J Nucl Med
– volume: 50
  start-page: 167
  year: 2011
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0185
  article-title: German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids
  publication-title: Nuklearmedizin Nuclear medicine
– volume: 32
  start-page: 1018
  year: 2005
  ident: 10.1016/j.nucmedbio.2020.02.006_bb0590
  article-title: O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-005-1819-7
SSID ssj0016410
Score 2.4312425
SecondaryResourceType review_article
Snippet The diagnostic potential of PET using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in brain tumor diagnostics has been proven in many...
The diagnostic potential of PET using the amino acid analogue O-(2-[ F]fluoroethyl)-L-tyrosine ([ F]FET) in brain tumor diagnostics has been proven in many...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 78
SubjectTerms Amino acids
Brain
Brain cancer
Brain metastasis
Brain tumor diagnosis
Brain tumors
Cerebral glioma
Diagnostic systems
Fluorine isotopes
Labeling
Magnetic resonance imaging
Methionine
Neuroimaging
O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
PET
Pharmacokinetics
Positron emission
Positron emission tomography
Radiolabelled amino acids
Tomography
Tracers
Tumors
Tyrosine
Title Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0969805120300299
https://dx.doi.org/10.1016/j.nucmedbio.2020.02.006
https://www.ncbi.nlm.nih.gov/pubmed/32113820
https://www.proquest.com/docview/2497224670
https://www.proquest.com/docview/2369876452
Volume 92
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Na9wwEB1CSksvpU3SZts0qJBDclBXlmzL21sIXbYfSQ9NILQUYcmzsGWxQ3Z92Et_e0eybMghpNCrrDGyZzTzRho9ARwpqyno2oKrsrA81crywtmKJ1hpO0mlTNCvQ55f5LOr9PN1dr0FZ_1ZGF9WGX1_59ODt44t4_g3xzeLxfg7ge9JQTYlyU4FeVV_gj3V3srf_xnKPCgbCIwEvjP3ve_UeNWto5hjF_4UoBQdeWd-X4S6D4GGSDR9Ds8ihGSn3ShfwBbWO_C4u1RyswNPzuN2OTWG-k632oUfkYeJrUMNLFvUjJAfa1fImjn7xo8l_5kU01_zZdvcNkjaW57wr3y9oSHSq9hxeDr9eHniRQMJZlMHwuvNHlxR-9mMx2sVuPO3F3BXpYQKnFVOIaEjVeUuryhHTnKn0wIJQDlKg3I5QUQrSGmZQEIpUrgCrc1K9RK266bGfWBOZphmEjOl555LzIq0TMRcEqoqS4fpCPL-VxoXOcf91RdL0xeX_TaDDozXgRHSkA5GIAbBm45242GRoteV6U-Vkh80FBoeFv0wiN4xvn8TPugNw8T5vzKU1GpP1afFCN4Nj2nm-u2YssampT6K7Ff7jeURvOoMavhWRXm5InD2-n9G9gaeSl-BExaMDmB7fdviW4JQa3sY5sghPDr99GV28ReEqBgV
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxsxEB5Shz4upU1fbtN2Cz0kB2GtpH24txBqnMZ2D00gtBSx0o7BxeyG2Hvwv-9Iq13IIaTQq6RZtJrRzCdp9AngszQZBV2TM1nkhqlMGpZbU7IYy8yMlRAxun3I-SKdXqpvV8nVHpx2d2FcWmXw_a1P9946lIzCaI6uV6vRDwLf45xsSpCdcvKqD2DfsVMlA9g_OTufLvrDhFR5UgLXnjmBW2leVWMp7JiVuwgoeMvfmd4VpO4CoT4YTZ7B04Aio5O2o89hD6sDeNi-K7k7gEfzcGJOhT7F025ewM9AxRRtfRpstKoiAn9Rs8GoXkbf2ZFgv-J88nu5buqbGkmB62M2Y9sddZE-FR352snXi2Mn6nkw68pzXu9ewiWVn05ZeFmBWfeAAbOlImBgjbQSCSDJMrVpScvkOLWZypEwlKWVUCrGiGg46S3hSEBFcJujMUkhX8Ggqit8A5EVCapEYCKzpaMTM1wVMV8KAlZFYVENIe2GUttAO-5ev1jrLr_sj-51oJ0ONBeadDAE3gtet8wb94vkna50d7GUXKGm6HC_6Jde9Jb9_ZvwYWcYOriAjaZ1bebY-jI-hE99NU1edyJTVFg31EaSCWfubHkIr1uD6v9V0tJcEj57-z89-wiPpxfzmZ6dLc7fwRPhEnL8_tEhDLY3Db4nRLU1H8KM-QsUpxrG
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+trends+in+the+use+of+O-%282-%5B18F%5Dfluoroethyl%29-L-tyrosine+%28%5B18F%5DFET%29+in+neurooncology&rft.jtitle=Nuclear+medicine+and+biology&rft.au=Stegmayr%2C+Carina&rft.au=Stoffels%2C+Gabriele&rft.au=Fil%CE%B2%2C+Christian&rft.au=Heinzel%2C+Alexander&rft.date=2021-01-01&rft.pub=Elsevier+BV&rft.issn=0969-8051&rft.eissn=1872-9614&rft.volume=92&rft.spage=78&rft_id=info:doi/10.1016%2Fj.nucmedbio.2020.02.006&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0969-8051&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0969-8051&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0969-8051&client=summon